belantamab mafodotin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antitumor, monoclonal antibodies 5405 2050232-20-5

Description:

MoleculeDescription

Molfile

Synonyms:

  • belantamab mafodotin
  • belantamab
  • belantamab mafodotin-blmf
  • blenrep
  • anti-BCMA-ADC
  • GSK2857914
  • GSK-2857916
  • J6M0-mcMMAF
Belantamab mafodotin-blmf is an antibody-drug conjugate (ADC). The antibody component is an afucosylated IgG1 directed against BCMA, a protein expressed on normal B lymphocytes and multiple myeloma cells. The small molecule component is MMAF, a microtubule inhibitor. Upon binding to BCMA, belantamab mafodotin-blmf is internalized followed by release of MMAF via proteolytic cleavage. The released MMAF intracellularly disrupts the microtubule network, leading to cell cycle arrest and apoptosis.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 25, 2020 EMA GlaxoSmithKline (Ireland) Limited
May 8, 2020 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 1046.01 68.78 124 959 492 63487447
Visual acuity reduced 568.54 68.78 118 965 21708 63466231
Night blindness 430.77 68.78 55 1028 428 63487511
Dry eye 237.21 68.78 66 1017 40695 63447244
Foreign body sensation in eyes 170.51 68.78 30 1053 2204 63485735
Death 123.46 68.78 77 1006 374304 63113635
Photophobia 104.17 68.78 29 1054 17606 63470333

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 1411.79 61.41 179 1252 466 34955034
Visual acuity reduced 677.96 61.41 151 1280 15998 34939502
Night blindness 471.58 61.41 61 1370 185 34955315
Dry eye 279.43 61.41 67 1364 9508 34945992
Foreign body sensation in eyes 174.87 61.41 29 1402 605 34954895
Photophobia 158.60 61.41 40 1391 6924 34948576
Punctate keratitis 116.04 61.41 19 1412 364 34955136
Corneal epithelial microcysts 115.71 61.41 13 1418 3 34955497
Corneal disorder 80.71 61.41 16 1415 918 34954582
Death 80.30 61.41 89 1342 397960 34557540
Keratitis 68.11 61.41 15 1416 1436 34954064
Corneal defect 63.74 61.41 7 1424 0 34955500

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Keratopathy 1947.38 46.85 244 1929 950 79741265
Visual acuity reduced 1009.98 46.85 217 1956 29252 79712963
Night blindness 692.84 46.85 90 2083 473 79741742
Dry eye 429.20 46.85 114 2059 36817 79705398
Foreign body sensation in eyes 301.52 46.85 52 2121 2105 79740110
Photophobia 198.60 46.85 55 2118 20473 79721742
Corneal epithelial microcysts 161.48 46.85 18 2155 13 79742202
Punctate keratitis 132.45 46.85 23 2150 963 79741252
Ocular toxicity 107.91 46.85 19 2154 862 79741353
Death 87.22 46.85 91 2082 566423 79175792
Corneal disorder 78.45 46.85 17 2156 2274 79739941
Keratitis 77.79 46.85 19 2154 4303 79737912
Corneal epithelium defect 71.53 46.85 13 2160 706 79741509
Corneal cyst 57.07 46.85 6 2167 0 79742215
Vision blurred 55.47 46.85 35 2138 105863 79636352
Corneal defect 51.99 46.85 6 2167 8 79742207

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX15 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Multiple myeloma indication 109989006 DOID:9538
Relapse multiple myeloma indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
IgG receptor FcRn large subunit p51 Membrane receptor BINDING AGENT Kd 7.28 DRUG LABEL DRUG LABEL
High affinity immunoglobulin gamma Fc receptor I Membrane receptor BINDING AGENT Kd 8.15 DRUG LABEL DRUG LABEL
Low affinity immunoglobulin gamma Fc region receptor III-A Membrane receptor BINDING AGENT Kd 7.55 DRUG LABEL DRUG LABEL
Tumor necrosis factor receptor superfamily member 17 Tumour-associated antigen BINDING AGENT Kd 9 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
D11595 KEGG_DRUG
DB1041CXDG UNII
2061894-48-0 SECONDARY_CAS_RN
C5227411 UMLSCUI
CHEMBL4298209 ChEMBL_ID
DB15719 DRUGBANK_ID
CHEMBL4298208 ChEMBL_ID
11117 IUPHAR_LIGAND_ID
018466 NDDF
895362005 SNOMEDCT_US
896748005 SNOMEDCT_US
4039621 VANDF
4039622 VANDF
10797 INN_ID
2387833 RXNORM
337068 MMSL
38715 MMSL
d09613 MMSL
C000631691 MESH_SUPPLEMENTAL_RECORD_UI
10754 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Blenrep HUMAN PRESCRIPTION DRUG LABEL 1 0173-0896 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections
Blenrep HUMAN PRESCRIPTION DRUG LABEL 1 0173-0896 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections
Blenrep HUMAN PRESCRIPTION DRUG LABEL 1 0173-0896 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections
Blenrep HUMAN PRESCRIPTION DRUG LABEL 1 0173-0896 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS BLA 28 sections